吉利德科学美股盘前涨近5%
Ge Long Hui A P P·2025-10-06 13:02
Core Viewpoint - Gilead Sciences' stock rose nearly 5% in pre-market trading following the announcement of a settlement agreement with Lupin, Cipla, and Laurus Labs to resolve the Biktarvy patent litigation [1] Group 1 - The settlement agreement aims to address ongoing patent disputes related to the Biktarvy drug [1] - The involvement of multiple pharmaceutical companies (Lupin, Cipla, and Laurus Labs) indicates a significant legal landscape surrounding Biktarvy [1] - The positive market reaction reflects investor confidence in Gilead Sciences' ability to navigate patent challenges effectively [1]